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Acute lymphoblastic leukemia is marked by aberrant transcriptional features that alter cell 
differentiation, self-renewal, and proliferative features. We sought to identify the transcription factors 
exhibiting altered and subtype-specific expression patterns in B-ALL and report here that SOX11, a 
developmental and neuronal transcription factor, is aberrantly expressed in the ETV6-RUNX1 and TCF3-
PBX1 subtypes of acute B-cell leukemias. We show that a high expression of SOX11 leads to alterations 
of gene expression that are typically associated with cell adhesion, migration, and differentiation. A 
high expression is associated with DNA hypomethylation at the SOX11 locus and a favorable outcome. 
The results indicate that SOX11 expression marks a group of patients with good outcomes and thereby 
prompts further study of its use as a biomarker.
SOX11 is a transcription factor (TF) encoded by the SOX11 gene located in chromosome 2p251. It is a mem-
ber of the SoxC (sex-determining region Y-related HMG box) group of genes and consists of two functional 
domains—the N-terminal DNA-binding and the C-terminal transactivation domains2,3. Other SoxC family 
members include SOX4 and SOX12. Of these, SOX4 is a crucial TF in B lymphopoiesis and is expressed in the 
B- and T-cell lineages2,4,5. SOX11 is normally expressed in the developing central nervous system of the embryo, 
in keratinocytes, and in some other epithelial tissues1,6–8. It is also expressed in ovarian and breast cancer, in which 
both tumor suppressor and oncogenic functions have been suggested9,10. A knockout mouse model revealed the 
vital role of SOX11 during embryonic development, as SOX11-deficient mice died after birth likely from multiple 
heart defects, asplenia, and organ hypoplasia in the lungs, stomach, and pancreas11. SOX11 deletions and muta-
tions are associated with neurodevelopmental disorders12.
Previous studies have shown that SOX11 mRNA and nuclear protein expression is a specific marker for con-
ventional but not indolent mantle cell lymphoma (MCL)8,13–15. In MCL, SOX11 has been associated with either 
increased or reduced cell proliferation16–23 and either good or bad prognosis24–27. In a cohort of 50 adult acute 
myeloid leukemia (AML) patients, a high SOX11 expression was associated with FLT/ITD and NPM1 mutations 
and a shortened disease-free survival28.
There is other evidence linking SOX11 with B-lineage malignancies. Dictor et al. (2009) reported that the 
nuclear expression of SOX11 was found in eight cases of B-lymphoblastic neoplasias29. Another study reported 
the strong nuclear expression of SOX11 in a single B-cell and five T-cell lymphoblastic lymphoma/leukemias13. 
Vegliante et al. (2011) demonstrated the increased expression of SOX11 mRNA in ETV6-RUNX1 (E/R) and 
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TCF3-rearranged B-cell precursor acute lymphoblastic leukemia (BCP-ALL)30, whereas Nordlund et al. (2012) 
and Busche et al. (2013) observed the prominent expression of SOX11 in the E/R subtype of ALL31,32.
We investigated the expression of SOX11 across lymphoid malignancies, focusing on B-lymphoblastic leu-
kemias. The function of SOX11 in leukemias and its clinical significance as a biomarker were further explored.
Materials and Methods
Microarray datasets. We used three independent datasets to study SOX11 expression—a combined 
microarray dataset (“Hemap”) retrieved from Gene Expression Omnibus (GEO)33,34, the GEO series GSE4705135, 
and the publicly available BCP-ALL data from the recent PanALL study36. The sample sizes for each dataset are 
shown in Supplementary Table 1.
Cell lines, cell culture, and drug treatments. NALM-6, REH, 697, RCH-ACV, KOPN-8, KASUMI-2, 
JURKAT, MOLT-16, P12-ICHIKAWA, HPB-ALL, and CCRF-CEM were cultured in RPMI Medium 1640 (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA) with 2 mM L-glut, 100 U penicillin, 100 µg/ml streptomycin with 
10% FBS (Gibco), and MOLT-4, PEER, and MHH-CALL3 with 20% FBS (Gibco) at 37 °C in 5% CO2. An induci-
ble E/R fusion in the NALM-6 cell line and a knockdown of E/R by a short hairpin RNA (shRNA) in the REH cell 
line have been previously described37. E/R expression was induced with 500 ng/ml doxycycline (Clontech). E/R 
expression changes were confirmed with RT-qPCR, with fusion gene-specific primers (Table S2). Mycoplasma 
tests were done regularly for the cell lines, and Eurofins Genomics (Ebersberg, Germany) services were used to 
authenticate the cell lines by STR genotyping. All cell lines used in this study were purchased from the Leibniz 
Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany).
For the methyltransferase inhibition experiments, the cultured cells were treated for 72 h with decitabine, 
5-Aza-2′-deoxycytidine solved in DMSO (A3656, Sigma-Aldrich, St. Louis, MO, USA) at 0, 0.1, and 1 µM con-
centrations. The media were changed at a 24 h interval to compensate for decitabine instability under cell culture 
conditions. After the treatment cells were collected, RNA was extracted for RT-qPCR analyses. Corticosteroid 
and chemotherapy treatments were conducted with the indicated concentration ranges, and cell viabilities were 
measured after either 72 (697 and RCH-ACV) or 96 h (REH). The corticosteroids included prednisolone (P6004, 
Sigma-Aldrich) and dexamethasone (D8893, Sigma-Aldrich), and the chemotherapy agents used were asparagi-
nase (A3809, Sigma-Aldrich) and vincristine (V8879, Sigma-Aldrich). The applied concentrations for each cell 
line are indicated in Table S3.
Quantitative real-time PCR. Total RNA was extracted using the PureLink™ RNA Mini Kit, and the 
On-Column PureLink® DNase Treatment Protocol was used for DNA removal (Ambion® by Life Technologies 
and Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA); 100–500 ng of the extracted RNA was used as a 
starting material for cDNA synthesis, which was performed with iScript (Bio-Rad, Hercules, CA, USA). RT-qPCR 
reactions were conducted according to the manufacturer’s instructions with SsoFast EvaGreen® Supermix 
(Bio-Rad). The following program was performed with the Bio-Rad CFX96TM Real-Time System (Bio-Rad): ini-
tial denaturation at 96 °C for 30 s, 39 cycles of denaturation at 96 °C for 2 s, annealing at 60 °C for 5 s, and plate 
read. Independent experiments performed in triplicate were used as the starting material for the RT-qPCR meas-
urements, and the relative 2−ΔΔCT method was used for quantification38. The primer sequences used in RT-qPCR 
are listed in Table S2.
Western blot. Protein extraction was performed using M-PER reagent (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions to lyse the cells, and protein concentrations were measured with DC 
Protein Assay (Bio-Rad); 15–20 µg of a protein sample was loaded into the precast 10% Mini-PROTEAN® TGX 
Stain-FreeTM Gels (Bio-Rad). After the electrophoresis run, Trans-Blot® TurboTM Pack (Bio-Rad) was used 
to transfer the proteins from the gel to the nitrocellulose membrane. Transfer was done with the Trans-Blot® 
TurboTM Transfer system according to the manufacturer’s instructions (Bio-Rad). A prestained protein lad-
der, PageRuler Plus (#26619, Thermo Fischer Scientific), was used as a protein size marker. We utilized anti-
bodies against SOX11 (1:1,000) (HPA000536, Sigma-Aldrich, Lot # BB107024) and Histone H3 (1:75,000) 
(ab4729, Abcam, Cambridge, UK, Lot # GR167613-1). Horseradish peroxidase conjugated anti-rabbit (1:2,000) 
(P0217, Lot # 00069121) was used as a secondary antibody (Agilent Technologies, Santa Clara, CA, USA). 
Chemiluminescence reaction by Amersham ECL reagent was detected with ChemiDocTM XRS+using Image 
LabTM Software (Bio-Rad).
Gene silencing with nucleofection. Knockdowns for suspension cells were performed using 
4D-Nucleofector™ (Lonza, Basel, Switzerland) for transfections. SOX11 knockdown was done using gene 
sequence-specific small interfering RNA (siRNA) (Sigma-Aldrich), and a non-specific siRNA was used as a 
control (Table S4). Before nucleofection, 20 µM stock solutions were diluted in Resuspension Buffer (SR30005, 
OriGene, Rockville, MD, USA) so that the final concentration per reaction was 300 nM. One million cells were 
used for each nucleofection reaction. Nucleofection reactions were conducted in proper solutions and programs 
according to the manufacturer’s instructions in single nucleocuvettes (Table S5). Then, the cells were transferred 
to 12-well plates with prewarmed fresh media. The transfected cells were used in cell viability assays and RNA 
sequencing (RNA-seq). Western blot and RT-qPCR were used to assess knockdown levels.
RNA sequencing of cell lines. SOX11-specific and control siRNAs were used in the nucleofection for the 
697, RCH-ACV, and REH cell lines to create SOX11 knockdown and control samples. After 48 h of nucleofection, 
three million cells per sample were collected for the total RNA extraction. RNA extraction was performed with 
the PureLink™ RNA Mini Kit, and the On-Column PureLink® DNase Treatment Protocol was used to avoid 
contamination by genomic DNA (Ambion® by Life Technologies and Invitrogen). Protein samples were also 
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collected, and the SOX11 knockdown level was verified by both RT-qPCR and Western blotting. Three independ-
ent biological replicates were collected for each transfected cell line, and each sample had 25 ng of RNA in 40 µl. 
Library preparation and RNA-seq (GSE123943) were performed in the Finnish Functional Genomics Centre 
(Turku, Finland). See more details in Supplementary Information.
The quality of the raw sequencing reads was ensured with FastQC (v0.10.1). Based on the FastQC results, 
reads were trimmed and their quality was filtered using the FASTX Toolkit (0.0.14). The reads were mapped to 
the human reference genome version hg19 using STAR aligner software (2.5.3a modified); reads aligning to more 
than two locations were discarded39. The alignment file was turned into tag directories, and read counts were 
calculated using the HOMER tool kit (v4.8).
Differential gene expression was analyzed using the quasi-likelihood F-test from edgeR, an R package40. 
Differentially expressed genes from all cell lines were filtered using the adjusted p-value < 0.05 (Benjamini–
Hochberg method) as a cut-off, and the resulting gene lists from three different cell lines were compared by draw-
ing a Venn diagram with an interactive Venn online tool (http://www.interactivenn.net/). Heatmaps, presenting 
all biological replicates, were drawn by using the z-scores of reads per kilobase of transcript, the per million 
mapped reads (RPKM) normalized count matrix, and the ComplexHeatmap R-package41. Gene set enrichment 
was analyzed by Gene Set Enrichment Analysis (GSEA) 3.0 software using logFC ranked lists of genes from dif-
ferential gene expression analysis, and the results presented had an adjusted p-value < 0.02 (Benjamini–Hochberg 
method)42,43. Gene ontology (GO) term enrichment was studied with two approaches—with GSEA software using 
f-statistics ranked lists of genes and with the GOrilla online tool using unranked target and background lists44,45. 
The target lists were created with a threshold of adjusted p-value < 0.05 and logFC >0.5 or <−0.5.
RNA sequencing and methylation analysis of the patient samples. Previous transcriptome 
sequencing of pediatric ALL cohort by Marincevic-Zuniga et al.46 included 116 BCP-ALL cases, of which 115 
cases were used to assess the SOX11 mRNA expression level in this study. DNA methylation data (GSE49031) 
were available for 112 of the 115 BCP-ALL cases35. See more details in Supplementary Information.
Cell viability and proliferation assays. Fresh media were replaced on the transfected cells after 24 h of 
transfection. For the cell viability assay, the cells were counted, and 10,000 cells per well were used in a 96-well 
plate. The cells were allowed to grow up to 72 (697 and RCH-ACV) and 120 h (REH), and cell viability was meas-
ured every 24 h with 10 µl of Alamar Blue reagent per well with a 2 h incubation before fluorescence measurement 
with excitation of 560 nm and emission of 590 nm using the Tecan fluorometer Infinite 200 (Tecan, Männedorf, 
Switzerland). For each time point, we used four technical replicates per sample to calculate the mean.
Cell proliferation assays were performed by counting the cells every 24 h after the transfection up to 96 (697 
and RCH-ACV) and 120 h (REH).
Clinical data and the patient samples. The data on pediatric ALL cases below 18 years of age and treated 
in the Tampere University Hospital were retrieved from the clinical registry from years 1990 to 2017. Essential 
clinical information, such as age, leukocyte count, gender, relapse, death, central nervous system leukemia, 
immunophenotype based on flow cytometry, and clinical genetic information, was collected. The study obtained 
permission from the local ethical committee, and informed consent was sought, as needed (Pirkanmaa Hospital 
District Ethical Committee, R16054 and R13109). The use of old biopsy samples was approved by the National 
Supervisory Authority for Welfare and Heath (Valvira), and the samples were handled in accordance with rele-
vant guidelines and regulations.
A total of 126 representative diagnostic formalin-fixed and paraffin-embedded (FFPE) decalcified bone mar-
row trephine biopsy samples were collected from the pathology department archives on the basis of the primary 
sample reports. For a proportion of cases, remission and relapse samples were also retrieved. Plastic-embedded 
and inadequate samples were excluded. The cases were classified based on the WHO 2017 Classification of 
Tumors and Haematopoietic and Lymphoid Tissues47.
Immunohistochemistry. Four micron-thick whole tissue sections were used for immunohistochemistry. 
All cases were stained with anti-SOX11 antibody (clone MRQ-58, Cell Marque, Sigma-Aldrich, Lot # 1331005 A 
and 1430213 C) using Ventana Benchmark Classic at a dilution of 1:50. FFPE human MCL was used as a positive 
control material, and remission bone marrow samples were used as negative controls.
Staining intensity was graded, and cases with less than 20% of positivity of leukemic blast cell nuclei were 
interpreted as negative. Cases with immunohistochemical positivity ranging from 20% to 50% in the blast cell 
nuclei were graded positive, and cases with immunohistochemical nuclear positivity of over 50% were considered 
strongly positive. SOX11 expression was independently analyzed with a light microscope by two experienced 
pathologists without knowledge of the clinical data. Cases with discrepant scores were further analyzed by a third 
pathologist.
fluorescence in situ hybridization. For cases lacking the genetic subtype information, fluorescence in 
situ hybridization analysis was performed on either the bone marrow aspiration samples or the FFPE samples. 
The following probes were used: Metasystems E2A Break Apart Probe 19p13 (Lot # 18216), Metasystems XL MLL 
plus Break Apart Probe 11q23 (Lot # 18451), Metasystems XL BCR/ABL1 plus (Lot # 19082), and Metasystems 
XL t(12;21) (Lot # 19133).
Flow cytometry analysis. For flow cytometry analysis, the cells were permeabilized using Fix&Perm rea-
gent according to the manufacturer’s instructions (GAS003, Invitrogen). The cells were then stained with Alexa 
Fluor 647® conjugated rabbit anti-human SOX11 antibody [EPR8191 (2)] (ab198540, Abcam), while CD3-APC 
antibody (345767) (Becton Dickinson, Franklin Lakes, NJ, USA) served as a negative control. The data were 
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acquired with the Beckman Coulter Navios cytometer (Beckman Coulter, Brea, CA, USA) using Red laser 
(638 nm) and 660/20 bandpass filter. Data analysis was conducted using Kaluza software (Beckman Coulter).
Statistical analysis. IBM SPSS Statistics (v. 22) and R (v. 3.40) were used for the statistical analysis. Kaplan–
Meier survival analysis was performed, and Log-rank test was used, with a p-value < 0.05 considered statistically 
significant. Event-free survival (EFS) was analyzed using death, relapse, resistant disease (blast count >25% at 
the end of induction), and secondary malignancy as events. Cox proportional hazards models were fitted to esti-
mate the effects of potential risk factors on survival. Chi-squared test was performed on SOX11 expression and 
clinicopathological prognostic variables. Kruskal–Wallis H and Mann–Whitney U tests were used to evaluate the 
differential expression of SOX11 in distinct leukemia subgroups (Table S6). All performed statistical tests were 
two tailed, and no corrections for multiple testing were used.
Results
SOX11 is overexpressed in acute lymphoblastic leukemias. Derailed differentiation and abnormal 
proliferation of B-cells are thought to underlie the genesis of BCP-ALL. As TFs are key cell differentiation drivers, 
we sought to identify aberrantly expressed TFs in BCP-ALL. We utilized a large, curated dataset of microar-
ray-based gene expression profiles retrieved from GEO34. This dataset comprises a total of 9,544 hematological 
gene expression profiles, including 4,418 leukemias, 428 healthy controls, and 862 cell lines. Among the genes 
with altered expression, TF SOX11 showed prominent expression in MCL and in the E/R and T/P subtypes of 
BCP-ALL (Fig. 1a). Compared with healthy hematopoietic cells, SOX11 had a 4.7- and 4-fold higher expression 
in the E/R and T/P subtypes, respectively, with an expression comparable to that in MCL (Fig. 1a). A similar 
subtype-specific expression of SOX11 was replicated in two additional ALL gene expression datasets (Fig. 1a). 
Interestingly, the PanALL study revealed that SOX11 expression is also elevated in novel subtypes, such as E/R-
like, IKZF1 N159Y (IKZF1 missense alteration encoding p.Asn159Tyr), MEF2D rearrangement, and DUX4 
rearrangement.
As SOX11 belongs to the SoxC family of TFs, we investigated the expression of the two other members of 
this family. SOX4, which has been reported to affect survival, progression, and proliferation in BCP-ALL48, was 
highly expressed in BCP-ALL and T-ALL, but it showed no subtype-specific expression pattern. The expression 
of SOX12 did not vary markedly between the studied subtypes (Fig. S1a).
A subtype-specific expression pattern was also present in BCP-ALL cell lines, as REH cells, representing the 
E/R subtype, and RCH-ACV and 697 cells, representing the T/P subtype, showed an increased expression of 
SOX11 by RT-qPCR (Fig. 1b). Neither knockdown of E/R in REH cells nor their overexpression in NALM-6 cells 
had any effect on SOX11 expression levels (Fig. S2a).
Immunohistochemical analysis of SOX11 expression in ALL. In order to confirm the SOX11 expres-
sion at the protein level and relate it to clinical features, we collected a retrospective cohort of 119 B-ALL cases 
with available bone marrow biopsies and associated clinical data (Table 1). We performed immunohistochem-
ical staining of the biopsy samples by using a SOX11-specific antibody. Staining intensity was graded from 0 to 
2, with 0 marking negative, 1 positive, and 2 strongly positive samples. Eighty out of 119 primary B-ALL bone 
marrow samples stained negative for SOX11, whereas 34 cases were positive and 5 were strongly positive (Fig. 2a 
and Table 2). A total of 29/39 (74.4%) of the positively staining B-ALL cases represented either the E/R or T/P 
subtype. A statistically significant association was observed with the E/R subtype (p-value < 0.001) but not with 
the T/P subtype (likely because of the low number of cases: N = 4, 3 positive cases). Cases with either KMT2A 
rearrangement or the Philadelphia chromosome (BCR-ABL1-translocation) did not express the SOX11 protein, 
and the majority of hyperdiploid cases were also SOX11 negative. Additionally, seven T-ALL cases included in the 
whole ALL patient cohort were all negative.
SOX11 expression is associated with a favorable outcome. We next sought to evaluate the clinical 
significance of SOX11 expression in B-ALL (N = 119). The overall survival (OS) was better in the SOX11-positive 
group, and no deaths occurred among SOX11-positive cases (p = 0.039) (Fig. 2b). The EFS and relapse-free sur-
vival (RFS) adjusted for the competing event (death) showed similar trends but did not reach statistical signifi-
cance (Fig. 2b). SOX11 positivity was not associated with good early therapy response, as measured by a minimal 
residual disease below 0.1% at the end of induction therapy (OR = 0.54, 95% CI 0.22, 1.28, p = 0.17). In multivar-
iate analysis of EFS with covariates (age, WBC, MRD and subtypes), a positive immunohistochemical staining for 
SOX11 protein showed a favorable trend (Table 3).
When SOX11 immunostaining positivity was analyzed separately within the E/R subtype, SOX11-positive 
cases had a better OS (Log-rank test p = 0.004), but EFS did not show a statistically significant difference with a 
hazard ratio of 0.67 (95% CI 0.07, 6.43).
We replicated the survival findings in another dataset. Transcriptomic data from a patient cohort comprising 
115 BCP-ALL cases were analyzed for SOX11 expression and patients’ survival status46. Figure 3a shows that a 
high SOX11 mRNA expression was associated with a favorable trend in EFS analysis.
SOX11 overexpression is associated with DNA hypomethylation. We next investigated the biol-
ogy behind the increased SOX11 expression in leukemia. Neither primary transcription (GRO-seq, N = 8) nor 
whole-genome sequencing (WGS, N = 8) of the SOX11 gene in BCP-ALL cases revealed any aberrant enhancer 
activity or somatic mutations, respectively, in the SOX11 gene or nearby regions (data not shown), prompting 
us to look for other mechanisms. In MCL, hypomethylation (partly) drives the increased SOX11 expression30. 
We utilized the above-mentioned BCP-ALL patient cohort with readily available genome-wide CpG meth-
ylation data35,46. Altogether, 23 CpG sites were located within the SOX11 gene locus, and a strong pattern of 
DNA hypomethylation was seen in patients with a high SOX11 mRNA expression (Fig. 3b,c). Nevertheless, 
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Figure 1. SOX11 expression in hematological malignancies. (a) Expression boxplots of SOX11 in healthy cells, 
leukemias, and mantle cell lymphoma. Data sources: Hemap microarray dataset34, GSE4705135, and the PanALL 
study36. See Supplementary Information for more details. (b) SOX11 expression in ALL cell lines and healthy 
B- and T-cells, as measured by RT-qPCR (N = 2, black lines indicate the median). ALL, acute lymphoblastic 
leukemia; AML, acute myeloid leukemia; BCL2/MYC, BCL2/MYC rearranged; BCP-ALL, B-cell precursor ALL; 
CRLF2, CRLF2 (non-Ph-like); DUX4, DUX4 rearranged; E/R, ETV6-RUNX1; HeH, high hyperdiploid; HLF, 
TCF3/TCF4-HLF; HSC, hematopoietic stem cell; iAMP21, intrachromosomal amplification of chromosome 21; 
IKZF1 N159Y, IKZF1 missense alteration encoding p.Asn159Tyr; KMT2A, KMT2A rearranged; MCL, mantle 
cell lymphoma; MEF2D, MEF2D rearranged; NUTM1, NUTM1 rearranged; PAX5alt, PAX5 alterations; PAX5 
P80R, PAX5 p.Pro80Arg (P80R) alteration; Ph, Philadelphia chromosome; T/P, TCF3-PBX1; ZNF384, ZNF384 
rearranged. Reproduced with permission66.
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DNA hypomethylation of the CpG sites at the SOX11 locus was not associated with a better EFS (Fig. 3a, right 
panel). We also tested whether a methyltransferase inhibitor, decitabine, could reverse SOX11 expression in leu-
kemia cell lines. After 72 h of decitabine treatment, a marked increase in SOX11 expression was observed in a 
concentration-dependent manner in KOPN-8 and REH cells (Figs. 3d and S2b).
WHO Subtype
Total/CombinedBurkitt NOS Ph KMT2A
ETV6-
RUNX1
Hyper-
diploid
Hypo-
diploid
TCF3-
PBX1
N of cases 2 42 2 5 33 30 1 4 119
Age, Md (min/max) 12.7 8.1 10.1 1.3 4 3.7 4.1 7.4 4.3 (0.9/17.6)
WBC count (109/l), Md (min/
max) 18.9 6.7 156.3 109.7 7 7.1 1.9 43.4 7.1 (1/311)
Deceased 2 6 1 0 1 1 0 0 9
Relapse 0 7 1 0 3 3 0 1 15
CNS disease 0 2 1 0 1 2 0 0 6
Resistant disease 0 3 0 0 1 0 0 0 4
MRD (%) at EOI, Md (min/max) 0 0.05 1.75 0 0.06 0 0 0 0.02 (0/44)
Follow-up (years), Md (min/max) 7.5 9.7 8.4 4 7.1 9.2 11.5 7.6 8.2 (0.1/17)
Table 1. Summary of clinical characteristics of B-ALL patients. CNS, central nervous system; EOI, end of 
induction therapy; KMT2A, KMT2A rearrangement; Max, maximum; Md, median; Min, minimum; MRD, 
minimal residual disease; NOS, not otherwise specified; Ph, Philadelphia chromosome; WBC, white blood cell.
Figure 2. SOX11 protein expression and impact on the outcome in BCP-ALL. (a) Expression of SOX11 protein 
by immunohistochemistry. Mantle cell lymphoma (MCL), a strongly positive case for SOX11 (400×); ALL1, 
a negative B-ALL case (400×); ALL2, a positive B-ALL case (400×); ALL3, a strongly positive B-ALL case 
(400×). (b) Kaplan–Meier survival curves and Log-rank p-values for OS, EFS, and RFS in the SOX11-positive 
(high) and -negative (low) groups. Reproduced with permission66.
SOX11 IHC
WHO Subtype
All casesBurkitt NOS Ph KMT2A ETV6-RUNX1 Hyper-diploid Hypo-diploid TCF3-PBX1
Negative 1 35 2 5 7 29 0 1 80
Positive 1 6 0 0 24 0 1 2 34
Strong positive 0 1 0 0 2 1 0 1 5
Total 2 42 2 5 33 30 1 4 119
Table 2. Summary of SOX11 protein expression by immunohistochemical staining in B-ALL. IHC, 
immunohistochemistry; KMT2A, KMT2A rearrangement; NOS, not otherwise specified; Ph, Philadelphia 
chromosome.
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N
MULTIVARIATE UNIVARIATE
HR 95% CI p-value HR 95% CI p-value
Age (years)
≥1 and ≤10 93 1.00* 1.00*
<1 and >10 26 0.87 0.31–2.38 0.79 1.27 0.50–3.23 0.61
WBC count (109/l)
<50 101 1.00* 1.00*
≥50 18 0.55 0.16–1.92 0.35 0.90 0.27–3.04 0.87
Subtype
Other B-ALL 56 1.00* 1.00*
High hyperdiploidy 30 0.27 0.07–1.00 0.05 0.45 0.15–1.36 0.16
ETV6-RUNX1 33 0.72 0.18–2.83 0.64 0.50 0.17–1.51 0.22
SOX11 expression
negative 80 1.00* 1.00*
positive 39 0.37 0.10–1.43 0.15 0.43 0.15–1.26 0.12
MRD at EOI
<0.1% 78 1.00* 1.00*
≥0.1% 37 1.70 0.68–4.24 0.26 2.18 0.94–5.06 0.07
Table 3. Multivariate and univariate analyses of the event-free survival based on expression level of SOX11 
protein in pediatric B-ALL. Cox proportional hazards regression calculated for known risk factors. SOX11 
expression was treated as a binary variable. 95% CI, 95% confidence interval; B-ALL, B-cell acute lymphoblastic 
leukemia; HR, hazard ratio; WBC, white blood cell. *Marks reference groups of each categorical variable.
Figure 3. Survival analysis and methylation status of cases with either a high or low SOX11 mRNA expression. 
(a) Kaplan–Meier survival curves and p-values of Log-rank test for EFS in patients with a low or high expression 
of SOX11 and in patients with a low or high methylation of the SOX11 gene locus. (b) CpG sites at the SOX11 
locus in chromosome 235. (c) DNA methylation at the SOX11 gene locus among patients with either a low or 
high expression of SOX11. (d) Effect of decitabine treatment on SOX11 mRNA expression in the KOPN-8 cell 
line. Reproduced with permission66.
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Knockdown of SOX11 alters gene sets related to cell development, motility, and drug response 
pathways. We next silenced SOX11 expression in three cell lines that overexpress SOX11 (REH, RCH-ACV, 
and 697) by using siRNA oligos. Figure 4a,b show that SOX11 expression was decreased to 20–40% at both the 
mRNA and protein levels compared with scrambled siRNA-transfected cells. Cell viability and proliferation 
assays did not demonstrate any significant changes (Figs. 4b and S4), and SOX11 knockdown did not have any 
impact on sensitivity to known leukemia drugs, such as dexamethasone, prednisolone, vincristine, and aspara-
ginase (Fig. S5).
As SOX11 is a TF and it regulates gene expression, we measured changes in gene expression after SOX11 
knockdown by using RNA-seq (GSE123943). Three biological replicates were used for each cell line (REH, 
RCH-ACV, and 697), and the data were analyzed using the R package EdgeR. In GO annotations, many of the 
altered terms were related to cell migration, adhesion, and differentiation (Fig. S6 and Supplementary Dataset). 
On the other hand, GSEA implied the altered expression of MYC and EF2 target genes (Figs. 4c and S6). SOX11 
knockdown did not have a significant effect on the expression of other SoxC family members, such as SOX4 and 
SOX12 (Fig. S7).
Figure 4. Cell viability and transcriptomic changes after knockdown of SOX11. (a) Expression level of SOX11 
after knockdown, as analyzed by RT-qPCR (N = 3, black lines indicate the median). (b) Knockdown of SOX11 
caused no evident changes in cell viability. Curves are drawn from the biological replicates using the median 
value at given time points. 697 and RCH-ACV cells represent the T/P subtype, and REH cells represent the E/R 
subtype. SOX11 knockdown was confirmed by Western blotting, and cell viability assessments were conducted 
with the AlamarBlue assay. Measured absorbance intensities are reported as x103 (697 N = 6; RCH-ACV and 
REH N = 4). Western blot gel figures are cropped per cell line from the original blot figures shown in Fig. S3. 
(c) SOX11 knockdown in 697 cells caused downregulation of genes that are known to be altered after MYC 
upregulation. (d) Venn diagram of differentially expressed genes in the REH, 697, and RCH-ACV cell lines after 
knockdown of SOX11 (adjusted p-value < 0.05). (e) Heatmap of 15 concordantly differentially expressed genes 
in all three cell lines after knockdown of SOX11. Reproduced with permission66.
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The Venn diagram in Fig. 4d shows that 18 genes were differentially expressed in all of the three cell lines 
after SOX11 knockdown (with an adjusted p-value < 0.05). Of these genes, 15 were concordantly down-regulated 
in all three cell lines and are shown in the heatmap (Fig. 4e, Supplementary Dataset). SOX11 knockdown led 
to the downregulation of the WD Repeat Domain 1 (WDR1) gene, which is involved in the remodeling of the 
actin cytoskeleton, regulation of cell migration, motility of neutrophils, and maturation of megakaryocytes49,50. 
Another gene down-regulated by SOX11 knockdown is Midkine (MDK), a secreted growth factor that pro-
motes cell migration and growth and is associated with an adverse prognosis in ALL possibly via increased 
drug resistance51,52. WW Domain Binding Protein 1 Like (WBP1L), also known as OPAL1 (outcome predictor 
for acute leukemia 1), which was recently identified as a direct target of ETV6 in ALL53, was down-regulated by 
SOX11 silencing. Previous reports on WBP1L’s association with a favorable prognosis have since been refuted54. 
However, WBP1L expression had a 2.8-fold increase in the E/R subtype55, which coincides with the overexpres-
sion of SOX11 in the same subtype and may suggest co-regulation. MLLT11 is involved in lymphoid regulation 
and is a known partner gene in rare leukemia translocations56,57. Similarly, Coiled-coil domain containing 28 A 
(CCDC28A) is a fusion partner to NUP98 in AML58. CANT1 is a calcium-dependent nucleotidase involved in 
pyrimidine metabolism whose regulation by SOX11 could be related with drug metabolism (cytarabine) and 
therapy response in ALL59. The lipopolysaccharide-induced TNF factor (LITAF) has been suggested to sensitize 
leukemia cells to chemotherapeutic drugs, especially in cells with a lower expression of LITAF60. Both LITAF and 
Sorting nexin 1 (SNX1) are involved in endosomal trafficking and regulation of cell-surface receptor signaling61,62. 
Taken together, SOX11 knockdown leads to alterations in genes and cellular processes related to leukemia cell 
motility, adhesion, differentiation, and drug response.
SOX11 protein can be detected by flow cytometry. Finally, we searched for flow cytometry markers 
that could serve as surrogates of SOX11 positivity. In MCL, the surface expression of CD5 is correlated with 
SOX11 positivity22, but in our immunohistochemical staining and microarray dataset34, no positive correlation 
was observed in leukemias (Fig. 5a). Alternative surrogate markers were searched for among the routinely studied 
cell surface proteins, but none were associated with SOX11 positivity (data not shown). Therefore, we explored 
the suitability of SOX11 antibodies to discriminate SOX11-positive cases by flow cytometry. Figure 5b shows 
that the intensity of SOX11 antibody staining could readily separate the high expressors (REH and RCH-ACV) 
from the low expressors (NALM-6 and KOPN-8) in leukemia cell lines, suggesting that SOX11 antibodies could 
possibly be used as a biomarker in the future.
Discussion
BCP-ALL is caused by a relatively small number of genetic mutations that impede normal B-cell differentiation, 
entail self-renewal capacity, and increase proliferative activity. This is evident in transcriptional programs that 
govern leukemic B-cells. We report here that SOX11, a developmental and neuronal TF6, is overexpressed in the 
E/R and T/P subtypes of BCP-ALL and also in novel E/R-like, IKZF1 N159Y, MEF2D rearrangement, and DUX4 
rearrangement subtypes. A high expression is associated with DNA hypomethylation and a favorable clinical 
Figure 5. Detection of SOX11-positive cells by flow cytometry in BCP-ALL. (a) Correlation of CD5 expression 
with SOX11 mRNA expression in the E/R and T/P subtypes of B-ALL and MCL34. SOX11 expression was 
categorized into three groups, not detected (ND), low and not detected (ND). (b) Flow cytometry analysis 
of nuclear SOX11 expression in cell lines with either a low (NALM-6, KOPN-8) or high (REH, RCH-ACV) 
expression of SOX11. ND, not detected, MCL, mantle cell lymphoma. Reproduced with permission66.
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outcome. The results suggest that a SOX11-associated transcriptional program is related with a less-aggressive 
disease and indicates that SOX11 warrants further study as a biomarker for low-risk ALL patients.
We observed the high expression of SOX11 in the E/R and T/P subtypes of BCP-ALL in three separate gene 
expression datasets at the mRNA level34–36 and confirmed this association at the protein level by immunohis-
tochemistry, confirming previously published data8,13,29,30 and adding further evidence at the protein level. We 
showed that the expression may be regulated epigenetically, that is, by hypomethylation of DNA at the SOX11 
locus, similar to what was earlier reported for MCL and five cases of BCP-ALL by Vegliante et al.30. We did not 
have material available for epigenetics studies, such as histone modifications, as these could also have a role in 
SOX11 regulation30. Direct manipulation of the E/R fusion did not have any impact on SOX11 expression, sug-
gesting that regulation is indirect.
An interesting finding relates to the clinical significance of SOX11 expression in BCP-ALL, as we observed 
a better OS in the SOX11-positive cases. A similar trend was also seen in EFS, RFS, and early therapy response. 
This finding was supported (similar trend) in another dataset with transcriptome expression profiles46. In the sub-
group analysis of E/R cases, SOX11 positivity retained its prognostic significance, suggesting that (a high) SOX11 
expression could possibly be utilized as a biomarker for cases with a very good prognosis. It is noteworthy that 
our immunohistochemical staining series spans almost two decades, and patients have been treated using several 
distinct NOPHO ALL chemotherapy protocols63,64. As the most recent protocols have conferred the best survival 
results [63, trying to replicate these findings in the most recent protocols is necessary in the future.
To aid in the screening of SOX11 positivity at diagnosis, we also successfully tested a flow cytometry-based 
assay in cell lines. SOX11 inclusion into the flow cytometry panel would be convenient compared with immuno-
histochemical staining of bone marrow biopsies, which is slow and not routinely done in all treatment centers.
SOX11 knockdown did not markedly influence cell viability or proliferation, nor did it affect chemotherapy 
sensitivity. In MCL, conflicting reports have been made about the effect of knockdown or SOX11 overexpression 
on cell proliferation and tumor growth16–23. As cell viability measurement is a relatively insensitive assay, we per-
formed transcriptional profiling of SOX11 knockdown cells by using RNA-seq and noticed changes in the genes 
associated with cell migration, adhesion, oxidative phosphorylation, hypoxia, glycolysis, and differentiation, 
which could explain the association of SOX11 with favorable clinical outcomes. Notably, the changes observed 
were mostly mild to moderate. There were only few overlapping genes with previous profiling studies in both 
pro-B-cells18 and MCL cells16,17,20,21,65. For example, we did not see marked changes in the expression of either 
PAX5, as seen in MCL21, or Id1 and Tal1 in pro-B-cells18. Interestingly, MDK, which is involved in cell migration 
and growth, was downregulated by SOX11 knockdown in leukemia cell lines here and in an MCL cell line Z13816.
In conclusion, the association of SOX11 expression with a favorable prognosis invites further studies to con-
firm its prognostic value and applicability as a part of the diagnostic workup.
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